Inroads in the therapy of indolent lymphomas: exploiting biological insights

Cancer Invest. 1999;17(1):73-86.
No abstract available

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Neoplasm / therapeutic use
  • Antimetabolites, Antineoplastic / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Apoptosis
  • Biomarkers, Tumor / analysis
  • Case Management
  • Clinical Trials as Topic
  • Genes, bcl-2
  • Humans
  • Immunologic Factors
  • Interferon-alpha / therapeutic use
  • Iodine Radioisotopes / therapeutic use
  • Lymphatic Irradiation
  • Lymphoma, Non-Hodgkin / classification
  • Lymphoma, Non-Hodgkin / genetics
  • Lymphoma, Non-Hodgkin / mortality
  • Lymphoma, Non-Hodgkin / pathology
  • Lymphoma, Non-Hodgkin / therapy*
  • Polymerase Chain Reaction
  • Prognosis
  • Proto-Oncogene Proteins c-bcl-2 / physiology
  • Radioimmunotherapy
  • Remission Induction
  • Survival Analysis
  • Translocation, Genetic

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neoplasm
  • Antimetabolites, Antineoplastic
  • Biomarkers, Tumor
  • Immunologic Factors
  • Interferon-alpha
  • Iodine Radioisotopes
  • Proto-Oncogene Proteins c-bcl-2